Printer Friendly

DISTINGUISHED ONCOLOGIST JOINS BOARD OF DIRECTORS OF U.S. BIOSCIENCE

 DISTINGUISHED ONCOLOGIST JOINS BOARD OF DIRECTORS
 OF U.S. BIOSCIENCE
 WEST CONSHOHOCKEN, Pa., June 8 /PRNewswire/ -- U.S. Bioscience Inc. (AMEX: UBS) announced today that Paul Calabresi, M.D., an internationally recognized authority on the pharmacology of anticancer agents, joined the company's board of directors.
 A member of the Institute of Medicine of the National Academy of Sciences, Calabresi is professor and chairman of the department of medicine at the Brown University School of Medicine. He recently received the Oscar B. Hunter Memorial Award in Therapeutics from the American Society of Clinical Pharmacology and Therapeutics. He has served as president of the American Society of Clinical Oncology, chairman of the Medical Oncology Committee of the American Board of Internal Medicine, and was a member of the board of directors of the American Association for Cancer Research. Calabresi has authored or edited more than 200 manuscripts and books on the pharmacology of anticancer agents and the management of cancer patients.
 Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases. The company's portfolio includes a broad spectrum of cancer drugs, including four products in the late stages of development. One compound, altretamine, is marketed under the name Hexalen(R) in the United States.
 -0- 6/8/92
 /CONTACT: Robert I. Kriebel of U.S. Bioscience, 215-832-4503; or Charles Versaggi of Versaggi & Associates, 408-358-4162 for U.S. Bioscience/
 (UBS) CO: U.S. Bioscience ST: California IN: MTC SU: PER


MM -- SJ003 -- 7723 06/08/92 08:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 8, 1992
Words:270
Previous Article:INFORMATION INTERNATIONAL TO ACQUIRE XITRON, EXPANDING BASE IN POSTSCRIPT LASER IMAGING SYSTEMS FOR NEWSPAPER, PUBLISHING COMPANIES
Next Article:VOLKSWAGEN EXTENDS LEASE PROGRAM TO HIGH-LINE MODEL
Topics:


Related Articles
U.S. BIOSCIENCE ANNOUNCES STOCK SPLIT
U.S. BIOSCIENCE ANNOUNCES STOCK SPLIT
DELAWARE VALLEY'S ENTREPRENEUR OF THE YEAR AWARD SELECTS PHILIP S. SCHEIN, M.D.
U.S. BIOSCIENCE APPOINTS REYNOLDS SENIOR MEDICAL DIRECTOR FOR R&D; CONLON AND KOUSSAI JOIN BIOSTATISTICS DEPARTMENT
MACMASTER, FORMER MERCK EXECUTIVE, NAMED TO U.S. BIOSCIENCE BOARD
MedImmune, Inc. to Acquire U.S. Bioscience, Inc. -Acquisition Provides Immediate Products and Infrastructure in Oncology-.
3DP Appoints Wendy L. Nagy Senior Vice President and General Counsel.
ParAllele Names Nick Naclerio President; Tom Willis, Ph.D., Becomes Chief Scientific Officer as Company Expands Commercial Focus.
New Colorado BioScience Association Forms; Colorado Biotechnology Association and Colorado Medical Device Association Merge.
Memory Pharmaceuticals Appoints Robert I. Kriebel to Board of Directors.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters